$18.17
+0.51 (+2.89%)
Open$17.85
Previous Close$17.66
Day High$18.21
Day Low$17.69
52W High$30.00
52W Low$3.42
Volume—
Avg Volume725.8K
Market Cap1.02B
P/E Ratio—
EPS$-3.31
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+149.6% upside
Current
$18.17
$18.17
Target
$45.36
$45.36
$37.53
$45.36 avg
$61.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 101.58M | 82.27M | 574.93M |
| Net Income | -142,562,027 | -103,925,015 | 29.33M |
| Profit Margin | -140.4% | -133.3% | 5.1% |
| EBITDA | -134,944,907 | -103,837,406 | 65.79M |
| Free Cash Flow | — | — | 30.48M |
| Rev Growth | +23.5% | +23.5% | -7.8% |
| Debt/Equity | — | — | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |